George Carrum is a Hematology physician affiliated with Baylor College of Medicine. OpenAlex indexes 198 publications with 7,443 citations (h-index 24); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6551 Bertner Ave Fl Wt15
Houston, TX 770302807
Telephone
713-441-1450Provider last certified this registry record 4 Oct 2024.
Clinical trials
- Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
Sponsor: Baylor College of Medicine
- Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20257 payments
- Kite Pharma, Inc.Program year20252 payments
- Celgene CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
36%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.4%Valacyclovir100%Part D≥28 patientsAzole Antifungal7.6%Posaconazole50%Fluconazole50%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
21.1%Proton pump inhibitor6.4%Pantoprazole Sodium100%Part D≥18 patientsBile Acid4.2%Ursodiol100%Part D≥11 patients+ 4 more classes in this area
Dermatology
9.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.4%Acyclovir100%Part D≥19 patientsCorticosteroid1.3%Triamcinolone Acetonide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2007–2007 per NIH RePORTER. The latest:
- TREATMENT OF CHRONIC LYMPHOCYTIC B-LEUKEMIA (B-CLL) WITH HUMAN IL-2 GENE MODI
Baylor College of Medicine
FY2007$1,171M01RR000188
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant
Biology of Blood and Marrow Transplantation
2024 - Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products
Biology of Blood and Marrow Transplantation
2021 - Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19
Biology of Blood and Marrow Transplantation
2021 - 37. Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T Cells Demonstrate Reactivity Against Emerging Variant Strains
Open Forum Infectious Diseases
2021 - The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Science Translational Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Christie Ballantyne, MD
Baylor College of Medicine
Biykem Bozkurt, MD
Baylor College of Medicine
William Mitch, MD
Baylor College of Medicine
Garabed Eknoyan, MD
Baylor College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”